Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Acerta Pharma BV
M.D. Anderson Cancer Center
AbbVie
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center